Dr. Willard is the President and Director of the Marine Biological Laboratory in Woods Hole, Massachusetts and Professor of Human Genetics at the University of Chicago. He previously held faculty positions at the University of Toronto, Stanford University, and Case Western Reserve University and most recently was the founding director of the Duke Institute for Genome Sciences & Policy and the Nanaline H. Duke Professor of Genome Sciences at Duke University. He is a respected leader in the fields of human genetics and genome biology and is the author or co-author of over 350 scientific publications. He is co-author of Genetics in Medicine and co-editor of Genomic and Personalized Medicine. Dr. Willard received his Ph.D. in human genetics from Yale University and is a member of both the National Academy of Sciences and the American Academy of Arts & Sciences.

Dr. Ulmann is Chairman of HRA Pharma, a company that he created in 1996 and managed until 2009. Under his leadership, HRA Pharma developed into a pharmaceutical leader in contraception and orphan diseases. Previously, Andre Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and HMR (later Sanofi-Aventis) with global responsibility in endocrinology, immunology, neurobiology, and bone diseases. Andre Ulmann holds an M.D. degree from the University of Paris VII and a Ph.D. from the University of Paris VI, France.

Daniel Ricquier, Ph.D. is Professor at University Paris Descartes and a member of the French Academy of Sciences. He previously held faculty and research positions at University Pierre and Marie Curie, Centre National de Recherches Scientifiques and Hôpital Necker-Enfants Malades.

He has conducted ground breaking and pioneering research on mitochondria bioenergetics, brown and white adipose tissues, energy balance and thermogenesis. He discovered uncoupling protein 1 (UCP1) and uncoupling protein 2 (UCP2) and went on to describe in details their roles in oxidative phosphorylation, thermogenesis, cardiovascular and metabolic diseases. He authored many manuscripts and reviews on uncoupling proteins, mitochondria, energy balance and obesity. As such, he is recognized as an international leader in these fields. Daniel Ricquier trained in physiology and biochemistry at Rouen University, Paris-Orsay University and Pierre and Marie University where he completed his Sc.D.

Mr. Poussot has been an Advisor for AptamiR since 2012. He was formerly the Chairman, CEO, & President of Wyeth Pharmaceuticals, until their acquisition by Pfizer in 2009. Earlier he held management positions at MSD and Searle in the United States and Europe. Mr. Poussot holds a degree from the Ecole Supérieure de Commerce de Paris.